Skip to main content
Industry News
Rivaroxaban similar to warfarin in subset of AF patients

Rivaroxaban showed similar results to warfarin in patients with atrial fibrillation and a bioprosthetic mitral valve for mean time to death, major cardiovascular events and major bleeding at 12 months, according to a study presented at the American Heart Association's virtual meeting and published in the New England Journal of Medicine. Dr. Donald Lloyd-Jones of Northwestern University commented that the study results could lead to broader use of rivaroxaban in patients with AF.

Full Story: